Today: 9 April 2026
American Express stock price: AXP ends Friday up, but the real read starts with the new 10-K
7 February 2026
2 mins read

American Express stock price: AXP ends Friday up, but the real read starts with the new 10-K

New York, Feb 7, 2026, 16:06 (EST) — The market is now closed.

  • American Express finished Friday’s session higher, with shares rising 1.28% to $359.15.
  • Investors are getting a closer look this week, thanks to a just-filed Form 10-K annual report.
  • A top executive has reported exercising stock options and selling shares, according to a Form 4 filing.

American Express (AXP) closed up 1.28% at $359.15 on Friday, stretching its winning streak to three sessions as U.S. equities surged heading into the weekend. The S&P 500 added 1.97% and the Dow jumped 2.47%. Volume on AXP hit roughly 3.3 million shares—beating the 50-day average—but shares are still 7.31% off the 52-week high. MarketWatch

Markets are closed Saturday, giving investors a chance to dive into American Express’ newly filed annual report. The company submitted its Form 10-K to the U.S. Securities and Exchange Commission on Feb. 6, covering financials for the year ended Dec. 31, 2025. SEC

The 10-K’s the spot for all the granular details: audited results, risk language, management’s take on credit and spending. Once earnings season wraps, this filing can flip the script—what investors thought they heard on the call, or brushed off as “one-off,” sometimes gets a rewrite here.

Traders might notice insider moves here. Anna Marrs—group president of Global Merchant and Network Services—exercised options and sold 27,425 shares on Feb. 5, pulling in a weighted average price near $350.01, according to a Form 4. (That’s the document insiders submit for stock transactions.) SEC

Still, American Express’ premium strategy isn’t without complications. Following January’s earnings, CFO Christophe Le Caillec told Reuters, “We’re not projecting any discontinuity,” but also pushed back against the proposed 10% credit card interest rate cap, arguing, “we just don’t think that the proposed cap would accomplish that goal.” The company is guiding for 2026 earnings per share between $17.30 and $17.90 with revenue growth in the 9% to 10% range. Truist analysts pointed out that the Platinum refresh increased costs, but didn’t translate into a clear rise in new accounts. Reuters

AXP tends to trade alongside other major financials, yet it’s got a distinct setup. American Express uses a closed-loop system, acting as both card issuer and network operator. That means shifts in billed business, credit losses, or marketing expenses can impact it in ways unlike Visa or Mastercard, who mostly just handle the payment rails.

Looking to Monday’s open, investors are eyeing whether Friday’s widespread risk appetite sticks around—and if the 10-K shifts sentiment on credit or costs. High rates plus weaker consumer data could put the premium-spend story under real pressure in a hurry.

Option-related insider selling happens all the time—on its own, it’s not much of a signal. Even so, it can muddy the waters for a stock that tends to react sharply to rumors about slowing travel or dining outlays, or talk of higher charge-offs.

Investors are eyeing Tuesday, when American Express management is scheduled for the UBS Financial Services Conference. The event kicks off Feb. 10 at 1:00 p.m. ET, and both a live webcast and a replay will be posted on the company’s investor relations site. ir.americanexpress.com

Stock Market Today

  • Guard Therapeutics Faces Potential Delisting from Nasdaq First North Growth Market
    April 9, 2026, 12:06 PM EDT. Guard Therapeutics International AB has been notified by Nasdaq that it currently fails to meet the active operations requirement, risking delisting by June 17, 2026. The company is exploring a merger or reverse acquisition to satisfy Nasdaq's operational criteria. A transaction structure is expected to be proposed in Q2 2024, allowing Nasdaq to reassess the listing status. If no agreement is reached, the board will recommend voluntary delisting and liquidation, returning available funds to shareholders. Final decisions will be taken by shareholders at a general meeting. Guard Therapeutics focuses on developing therapies for kidney diseases based on the alpha-1-microglobulin protein and is listed under the ticker GUARD.

Latest article

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

9 April 2026
Palantir Technologies dropped about 7% Thursday after Michael Burry said Anthropic was overtaking it in enterprise AI, putting Palantir on track to lose $34 billion in market value. Anthropic reported its annualized revenue run rate had surged past $30 billion and launched new AI tools for businesses. Nearly one in four businesses on Ramp now pays for Anthropic, according to Ramp data. Palantir’s stock still trades at 395 times earnings.
Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
UnitedHealth stock price ticks up to $276.65 as insurer cost signals shift — what investors watch next week
Previous Story

UnitedHealth stock price ticks up to $276.65 as insurer cost signals shift — what investors watch next week

McDonald’s stock nears a 52-week high heading into earnings week: what to watch next
Next Story

McDonald’s stock nears a 52-week high heading into earnings week: what to watch next

Go toTop